Descriptions

The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.

Autoinhibitory domains (AIDs)

Target domain

Relief mechanism

Assay

cis-regPred

Accessory elements

No accessory elements

Autoinhibited structure

Activated structure

1 structures for Q9FN29

Entry ID Method Resolution Chain Position Source
AF-Q9FN29-F1 Predicted AlphaFoldDB

15 variants for Q9FN29

Variant ID(s) Position Change Description Diseaes Association Provenance
tmp_5_21914103_G_C 6 S>T No 1000Genomes
ENSVATH07413522 8 G>S No 1000Genomes
ENSVATH00732701 22 Q>K No 1000Genomes
ENSVATH00732704 63 F>S No 1000Genomes
ENSVATH00732706 79 H>L No 1000Genomes
ENSVATH03424271 80 E>K No 1000Genomes
ENSVATH12750034 86 K>N No 1000Genomes
ENSVATH07413524 103 A>T No 1000Genomes
tmp_5_21914411_C_A 109 L>M No 1000Genomes
tmp_5_21914414_T_C 110 F>L No 1000Genomes
ENSVATH07413525 117 V>F No 1000Genomes
ENSVATH12750076 124 S>Y No 1000Genomes
ENSVATH12750077 134 V>L No 1000Genomes
ENSVATH00732708 146 N>S No 1000Genomes
ENSVATH12750078 149 G>E No 1000Genomes

6 associated diseases with Q9FN29

[MIM: 192600]: Cardiomyopathy, familial hypertrophic, 1 (CMH1)

A hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death. . Note=The disease is caused by variants affecting the gene represented in this entry.

[MIM: 608358]: Congenital myopathy 7A, myosin storage, autosomal dominant (CMYP7A)

A skeletal muscle disorder characterized by prominent axial and proximal weakening, spinal stiffness, severe scoliosis, with or without respiratory and cardiac involvement. The age at symptom onset can range from early childhood to late adulthood, and disease severity ranges from asymptomatic to severe muscular weakness and respiratory insufficiency. Histopathological examination shows variable findings including subsarcolemmal hyaline bodies in type 1 fibers. . Note=The disease is caused by variants affecting the gene represented in this entry.

[MIM: 613426]: Cardiomyopathy, dilated, 1S (CMD1S)

A disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. . Note=The disease is caused by variants affecting the gene represented in this entry.

[MIM: 160500]: Myopathy, distal, 1 (MPD1)

A muscular disorder characterized by early-onset selective weakness of the great toe and ankle dorsiflexors, followed by weakness of the finger extensors. Mild proximal weakness occasionally develops years later after the onset of the disease. . Note=The disease is caused by variants affecting the gene represented in this entry.

[MIM: 255160]: Congenital myopathy 7B, myosin storage, autosomal recessive (CMYP7B)

A skeletal muscle disorder characterized by the onset of scapuloperoneal muscle weakness in early childhood or young adulthood. Affected individuals have difficulty walking, steppage gait, and scapular winging due to shoulder girdle involvement. The severity and progression of the disorder is highly variable. Most patients develop respiratory insufficiency and restrictive lung disease. Some develop hypertrophic cardiomyopathy. Histopathological examination shows variable findings including subsarcolemmal hyaline bodies in type 1 fibers. . Note=The disease is caused by variants affecting the gene represented in this entry.

[MIM: 613426]: Left ventricular non-compaction 5 (LVNC5)

A form of left ventricular non-compaction, a cardiomyopathy due to myocardial morphogenesis arrest and characterized by a hypertrophic left ventricle, a severely thickened 2-layered myocardium, numerous prominent trabeculations, deep intertrabecular recesses, and poor systolic function. Clinical manifestations are variable. Some affected individuals experience no symptoms at all, others develop heart failure. In some cases, left ventricular non-compaction is associated with other congenital heart anomalies. LVNC5 is an autosomal dominant condition. . Note=The disease is caused by variants affecting distinct genetic loci, including the gene represented in this entry.

Without disease ID
  • A hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death. . Note=The disease is caused by variants affecting the gene represented in this entry.
  • A skeletal muscle disorder characterized by prominent axial and proximal weakening, spinal stiffness, severe scoliosis, with or without respiratory and cardiac involvement. The age at symptom onset can range from early childhood to late adulthood, and disease severity ranges from asymptomatic to severe muscular weakness and respiratory insufficiency. Histopathological examination shows variable findings including subsarcolemmal hyaline bodies in type 1 fibers. . Note=The disease is caused by variants affecting the gene represented in this entry.
  • A disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. . Note=The disease is caused by variants affecting the gene represented in this entry.
  • A muscular disorder characterized by early-onset selective weakness of the great toe and ankle dorsiflexors, followed by weakness of the finger extensors. Mild proximal weakness occasionally develops years later after the onset of the disease. . Note=The disease is caused by variants affecting the gene represented in this entry.
  • A skeletal muscle disorder characterized by the onset of scapuloperoneal muscle weakness in early childhood or young adulthood. Affected individuals have difficulty walking, steppage gait, and scapular winging due to shoulder girdle involvement. The severity and progression of the disorder is highly variable. Most patients develop respiratory insufficiency and restrictive lung disease. Some develop hypertrophic cardiomyopathy. Histopathological examination shows variable findings including subsarcolemmal hyaline bodies in type 1 fibers. . Note=The disease is caused by variants affecting the gene represented in this entry.
  • A form of left ventricular non-compaction, a cardiomyopathy due to myocardial morphogenesis arrest and characterized by a hypertrophic left ventricle, a severely thickened 2-layered myocardium, numerous prominent trabeculations, deep intertrabecular recesses, and poor systolic function. Clinical manifestations are variable. Some affected individuals experience no symptoms at all, others develop heart failure. In some cases, left ventricular non-compaction is associated with other congenital heart anomalies. LVNC5 is an autosomal dominant condition. . Note=The disease is caused by variants affecting distinct genetic loci, including the gene represented in this entry.

11 regional properties for Q9FN29

Type Name Position InterPro Accession
domain Protein kinase domain 696 - 951 IPR000719
domain Immunoglobulin subtype 335 - 419 IPR003599-1
domain Immunoglobulin subtype 475 - 559 IPR003599-2
domain Immunoglobulin subtype 1047 - 1132 IPR003599-3
domain Fibronectin type III 562 - 657 IPR003961
domain Immunoglobulin-like domain 329 - 417 IPR007110-1
domain Immunoglobulin-like domain 469 - 557 IPR007110-2
domain Immunoglobulin-like domain 1041 - 1130 IPR007110-3
active_site Serine/threonine-protein kinase, active site 813 - 825 IPR008271
domain Myosin Light Chain Kinase 1, Kinase domain 693 - 951 IPR015725
binding_site Protein kinase, ATP binding site 702 - 725 IPR017441

Functions

Description
EC Number
Subcellular Localization
  • Nucleus
PANTHER Family
PANTHER Subfamily
PANTHER Protein Class
PANTHER Pathway Category No pathway information available

1 GO annotations of cellular component

Name Definition
nucleus A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent.

4 GO annotations of molecular function

Name Definition
DNA-binding transcription factor activity A transcription regulator activity that modulates transcription of gene sets via selective and non-covalent binding to a specific double-stranded genomic DNA sequence (sometimes referred to as a motif) within a cis-regulatory region. Regulatory regions include promoters (proximal and distal) and enhancers. Genes are transcriptional units, and include bacterial operons.
DNA-binding transcription factor activity, RNA polymerase II-specific A DNA-binding transcription factor activity that modulates the transcription of specific gene sets transcribed by RNA polymerase II.
sequence-specific DNA binding Binding to DNA of a specific nucleotide composition, e.g. GC-rich DNA binding, or with a specific sequence motif or type of DNA e.g. promotor binding or rDNA binding.
transcription cis-regulatory region binding Binding to a specific sequence of DNA that is part of a regulatory region that controls transcription of that section of the DNA. The transcribed region might be described as a gene, cistron, or operon.

3 GO annotations of biological process

Name Definition
positive regulation of DNA-templated transcription Any process that activates or increases the frequency, rate or extent of cellular DNA-templated transcription.
response to absence of light Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an absence of light stimuli.
response to blue light Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a blue light stimulus. Blue light is electromagnetic radiation with a wavelength of between 440 and 500nm.

20 homologous proteins in AiPD

UniProt AC Gene Name Protein Name Species Evidence Code
P50577 DLX5 Homeobox protein DLX-5 Gallus gallus (Chicken) PR
Q03014 HHEX Hematopoietically-expressed homeobox protein HHEX Homo sapiens (Human) PR
O60479 DLX3 Homeobox protein DLX-3 Homo sapiens (Human) PR
P56179 DLX6 Homeobox protein DLX-6 Homo sapiens (Human) PR
O95076 ALX3 Homeobox protein aristaless-like 3 Homo sapiens (Human) PR
Q99801 NKX3-1 Homeobox protein Nkx-3.1 Homo sapiens (Human) PR
P70396 Dlx5 Homeobox protein DLX-5 Mus musculus (Mouse) PR
Q64205 Dlx3 Homeobox protein DLX-3 Mus musculus (Mouse) PR
P70397 Dlx6 Homeobox protein DLX-6 Mus musculus (Mouse) PR
P50575 Dlx5 Homeobox protein DLX-5 Rattus norvegicus (Rat) PR
Q6H6S3 HOX24 Homeobox-leucine zipper protein HOX24 Oryza sativa subsp japonica (Rice) PR
Q7XUJ5 HOX22 Homeobox-leucine zipper protein HOX22 Oryza sativa subsp japonica (Rice) PR
Q5VPE5 HOX28 Homeobox-leucine zipper protein HOX28 Oryza sativa subsp japonica (Rice) PR
A3BYC1 HOX25 Homeobox-leucine zipper protein HOX25 Oryza sativa subsp japonica (Rice) PR
P46603 HAT9 Homeobox-leucine zipper protein HAT9 Arabidopsis thaliana (Mouse-ear cress) PR
Q9M276 ATHB-12 Homeobox-leucine zipper protein ATHB-12 Arabidopsis thaliana (Mouse-ear cress) PR
Q98875 dlx1a Homeobox protein Dlx1a Danio rerio (Zebrafish) (Brachydanio rerio) PR
Q98878 dlx4b Homeobox protein Dlx4b Danio rerio (Zebrafish) (Brachydanio rerio) PR
P50574 dlx2a Homeobox protein Dlx2a Danio rerio (Zebrafish) (Brachydanio rerio) PR
Q01702 dlx3b Homeobox protein Dlx3b Danio rerio (Zebrafish) (Brachydanio rerio) PR
10 20 30 40 50 60
MENSQSQGKN KKKRLTQDQV RQLEKCFTMN KKLEPDLKLQ LSNQLGLPQR QVAVWFQNKR
70 80 90 100 110 120
ARFKTQSLEV QHCTLQSKHE AALSDKAKLE HQVQFLQDEL KRARNQLALF TNQDSPVDNS
130 140 150
NLGSCDEDHD DQVVVFDELY ACFVSNGHGS SSTSWV